Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-years outcome compared to persistent low-remission status and represent a heterogeneous group.

Irini Genitsaridi
University of Crete School of Medicine  https://orcid.org/0000-0001-7196-7081

Irini Flouri
University of Crete School of Medicine

Dimitris Plexousakis
Idryma Technologias kai Ereunas

Konstantinos Marias
Technical University of Crete

Kyriaki Boki
Rheumatology Department, "Sismanoglio" Hospital, Athens

Fotini Skopouli
Harokopio University

Alexandros Drosos
University Hospital of Ioannina

George Bertsias
University of Crete School of Medicine

Dimitrios Boumpas
National and Kapodistrian University of Athens Faculty of Medicine

Prodromos Sidiropoulos (暕 sidiropp@uoc.gr )  https://orcid.org/0000-0001-9607-0326

Research article

Keywords: Persistent Moderate Rheumatoid Arthritis, Biologics, Functionality, Serious Adverse Events, Heterogeneity

DOI: https://doi.org/10.21203/rs.3.rs-41068/v2
Abstract

Background The long-term outcome of rheumatoid arthritis (RA) patients who in clinical practice exhibit persistent moderate disease activity (pMDA) despite treatment with biologics has not been adequately studied. Herein, we analyzed the 5-year outcome of the pMDA group and assessed for within-group heterogeneity.

Methods We included longitudinally-monitored RA patients from the Hellenic Registry of Biologic Therapies with persistent (cumulative time ≥50% of a 5-year period) moderate (pMDA, 3.2<\text{DAS28}\leq 5.1) or remission/low (pRLDA, \text{DAS28}\leq 3.2) disease activity. The former was further classified into persistent lower-moderate (plMDA, \text{DAS28}<4.2) and higher-moderate (phMDA, \text{DAS28}\geq 4.2) subgroups. Five-year trajectories of functionality (HAQ) was the primary outcome in comparing pRLDA versus pMDA and assessing heterogeneity within the pMDA subgroups through multivariable mixed-effect regression. We further compared serious adverse events (SAEs) occurrence between the two groups.

Results We identified 295 patients with pMDA and 90 patients with pRLDA, the former group comprising of plMDA (n=133, 45%) and phMDA (n=162, 55%). pMDA was associated with worse 5-year functionality trajectory than pRLDA (+0.27 HAQ units, CI 95% +0.22 to +0.33; p<0.0001), while the phMDA subgroup had worse 5-year functionality than plMDA (+0.26 HAQ units, CI 95% 0.18 to 0.36; p<0.0001). Importantly, higher persistent disease activity was associated with more SAEs [pRLDA: 0.2±0.48 vs pMDA: 0.5±0.96, p=0.006; plMDA: 0.32 ±0.6 vs phMDA: 0.64 ±1.16, p=0.038]. Male gender (p=0.017), lower baseline DAS28 (p<0.001), HAQ improvement >0.22 (p=0.029) and lower average DAS28 during the rst trimester since treatment initiation (p=0.001), independently predicted grouping into pRLDA.

Conclusions In clinical practice, RA patients with pMDA while on bDMARDs have adverse long-term outcomes compared to lower disease activity status, while heterogeneity exists within the pMDA group in terms of 5-year functionality and SAEs. Targeted studies to better characterize pMDA subgroups are needed, in order to assist clinicians in tailoring treatments.

Background

Rheumatoid arthritis (RA) disease activity state is associated with long-term prognosis (1). According to the widely accepted treat-to-target (T2T) strategy, the aim of treatment in RA is to improve patients’ health-related quality of life by abrogation of inflammatory burden (2). T2T approach in RA aims remission or low disease activity, evaluated by composite indexes such as the disease activity score of 28 joint counts (DAS28) (3). Biologic disease-modifying antirheumatic drugs (bDMARDs) are potent agents which control inflammation and improve prognosis. Their clinical effectiveness has been extensively reported in controlled clinical trials and registries. Data from registries have shown that 15–35% of patients treated with TNFα inhibitors (TNFis) achieve remission at 12 months (4–7) and figures are comparable with non-TNFis such as tocilizumab (8). Interestingly, approximately 30–50% of patients
although improve disease activity, they still have moderate disease activity (MDA) after treatment with
the first bDMARD (6).

Outcomes of patients with residual MDA while on treatment are available only from trials focusing on
early-onset disease treated with conventional synthetic DMARDs (csDMARDs) (9, 10) and a pooled
analysis of randomized controlled clinical trials of TNFis reported on early (1-year) outcomes (1).
Moreover, most of the registries report on disease activity status at prespecified time-points after
treatment, while data indicative of long-term longitudinal disease activity course (i.e. time-averaged
disease activity) are limited. To this end, data for RA patients on bDMARDs having persistently MDA are
scant. Rheumatologists in clinical practice often confront with patients who have residual disease
activity even after switching biologic disease modifying drugs. Therefore, and given the lack of data for
this group, we sought to assess the long-term outcome of RA patients on bDMARDs who exhibit
persistent moderate disease activity (pMDA) in clinical practice context.

Herein, we analyzed data from the Hellenic Registry of Biologic Therapies to evaluate the long-term (5-
years) outcome of RA patients on bDMARDs who exhibit pMDA. We aimed to compare the functional
status (HAQ) at 5 years and its longitudinal course (trajectories) in patients with pMDA versus those on
persistent lower inflammatory burden, as well as to assess for clinical heterogeneity within pMDA. We
also looked for early predictors of patients’ classification into the distinct persistent disease activity
groups.

**Methods**

**Data source**

The Hellenic Registry of Biologic Therapies (HeRBT) was established in 2004 as a multicenter (7 centers)
prospective observational cohort of patients with inflammatory arthritides (6). RA and spondyloarthritis
patients are included in the HeRBT at the initiation of first bDMARD and are followed-up for as long as
they receive bDMARDs. Detailed analysis of protocol is given elsewhere (6, 11). Treatment decisions
(bDMARD selection, co-medication, dosage adjustments/switches) were made at the discretion of
treating rheumatologists based on clinical assessments, national guidelines and patient's preferences.
Ethical approval was obtained from the Institutional Review-Board of the University Hospital of Heraklion,
Crete (decision-number:1476/20-03-2012) along with participants’ informed consents.

**Patients**

We analyzed all adult patients diagnosed with RA who were registered for the first time in HeRBT until
31/5/2013 and had continuous follow-up for at least 5 years, irrespective of bDMARD treatment
switches. Data were censored when patients completed 5 years of follow-up.

**Longitudinal clinical data**
Data harmonization was performed to summarize longitudinal disease activity (assessed by DAS28 index) and functionality (assessed by Health-Assessment-Questionnaire (HAQ)) assessments in clinically relevant therapy time (TT) intervals. Specifically, we defined a total of eight TT intervals spanning sequentially over the 5 years follow-up period, which included six semesterly for the first 2 years, followed by 3 yearly time-intervals. DAS28 and HAQ averages were computed for each patient, in each TT interval, from all clinical assessments conducted in the specific time period.

**Definitions and clustering by persistent disease activity**

Patients were classified into persistent low (pRLDA) and persistent moderate (pMDA) disease activity groups, if they correspondingly had DAS28 \( \leq 3.2 \) and \( 3.2 < \text{DAS28} \leq 5.1 \) for cumulative time percentage \( \geq 50\% \) of the 5-year follow-up time. Cumulative time percentage (CTP) of a DAS28 range was defined as the ratio of TT intervals that have DAS28 in the specific range. A patient was clustered in a persistent disease activity group when a specific DAS28-range occurred for CTP \( \geq 50\% \) or equivalently for at least 4 out of the 8 TT intervals (any of them).

To assess for within-group heterogeneity, patients with pMDA were further sub-divided into persistent lower-moderate (plMDA) and higher-moderate (phMDA) disease activity groups, when they fulfilled the additional criterion of having persistent \( \text{DAS28} < 4.2 \) and \( \text{DAS28} \geq 4.2 \), respectively for CTP \( \geq 50\% \), as defined above. Any conflicting cases, where patients could be classified in two different persistent disease activity groups, were resolved by the preference policy of the worst-case scenario (classification in the higher disease activity group).

**Statistical analysis**

Summary descriptive measures were used on baseline characteristics of the persistent disease activity groups. Non-parametric hypothesis tests (Kruskal-Wallis, Wilcoxon rank-sum, and chi-squared, as appropriate) were used to compare groups’ differences at baseline characteristics (Bonferroni-corrected p-value=0.0019 to account for multiple comparisons) and also to compare groups’ 5-year outcomes regarding functional status (HAQ) and cumulative serious adverse events (SAEs). To estimate the required sample size to compare functionality, we formulated the null hypothesis that functionality (HAQ) at 5 years would not differ significantly between pRLDA and pMDA groups (i.e. difference in HAQ \( \leq 0.22 \) units). To reject this null hypothesis with 80% power (\( \alpha=0.05 \)) and assuming 0.5 mean HAQ (0.5 std) in the pMDA and 0.28 in the pRLDA group and patient allocation ratio pRLDA:pMDA to be 1:2, the estimated required sample size was at least 61 and 122 patients in the pRLDA and pMDA groups, respectively.

Multivariable mixed-effect regression analysis was used to associate the persistent disease activity groups pRLDA and pMDA with different 5-year functionality trajectories. Additionally, multivariable mixed-effect regression was performed for pMDA group to assess for clinical heterogeneity (5-year functionality trajectories) between plMDA and phMDA subgroups. In the analyses, HAQ was modeled as the dependent outcome variable while the persistent disease activity group (or subgroup) was modeled as fixed-effect variable (categorical, dummy-coded with reference-category the lower persistent disease activity group).
We accounted for individual patient variability with a random effect on the patient level (random intercept for each patient) and adjusted for possible confounding effects of gender, age and disease duration (fixed-effects). Time in treatment course was modeled as fixed-effect categorical variable (dummy-coded, 9-values, reference-category baseline, remaining values represent the 8 TT intervals). This time representation was selected to model the change in HAQ in each TT interval compared to baseline. Alternative representations of groups’ interactions with time did not yield significantly better results on comparison metrics of AIC, BIC and negative log-likelihood.

Multivariable logistic regression was also performed to analyze for early predictors that classify in pMDA (versus pRLDA) group. The model was adjusted for gender, age (per year), disease duration (per year) and previous csDMARDs at baseline (binary, true for csDMARDs<2). The model also included the following patient’s characteristics from baseline and first therapy semester: baseline disease activity (DAS28), baseline functionality (HAQ), anti-TNF treatment initiation, average disease activity in first semester (DAS28-average) and functionality difference (ΔHAQ) in first semester’s average (HAQ-average) from baseline (binary, true for difference<0.22). Predictive efficiency of the model was evaluated using the 10-fold cross-validation process (90% training set, 10% test set and 10 repetitions without resubstitution) in the samples of the analysis cohort, in order to avoid overfitting and selection bias. The efficiency metrics, accuracy (ACC), sensitivity or true positive rate (TPR), specificity or true negative rate (TNR) and the area under the receiver-operating-characteristic curve (AUC), were averaged from 10 independent datasets extracted from the cross-validation process.

**Missing data management**

Patients who had proportionally more missing than existing DAS28-assessments, were excluded in order to maintain data quality. Missing DAS28-data in the rest of the patients, were imputed with a multivariable mixed-effect regression model, due to the time-dependent nature of the longitudinal DAS28-data (repeated correlated DAS28-measurements in the same patients). The model was adjusted on gender, age and disease duration (fixed-effects) and included a random effect on the patient level and a fixed-effect variable for time (as in the aforementioned mixed-effect model). All analyses were performed in MATLAB 9.2 statistical toolbox.

**Results**

**Cohort characteristics**

The analysis cohort included 385 patients from the HeRBT registry that fulfilled two criteria, (a) they had at least 5 years follow-up and (b) they exhibited persistent low or moderate disease. This cohort was selected out of the 1466 RA patients included in the registry until May 2013, after excluding 763 patients due to < 5 years follow-up, 166 patients having missing longitudinal DAS28-data > 50%, 142 exhibiting persistent high inflammatory burden and 10 patients not exhibiting any persistent disease activity level. This was a cohort mostly with established RA (mean disease duration 9.2 years), 70 patients had disease duration < 2 years and the mean monitoring duration was 7.5 years (Table 1). Patients were treated with
an average of 2.34 (± 1.13) csDMARDs prior to first bDMARD, while 279 (72%) were on combination with methotrexate. At the end of 5 years, 208 (54%) patients received a second and 99 (26%) received a third sequential bDMARD.
Table 1
Baseline characteristics of patient cohort and the different persistent disease activity groups. §

| Variable Name         | Cohort (n = 385) | RemissionLow pRLDA (n = 90) | Moderate pMDA (n = 295) | lower-Moderate pMDA (n = 133) | higher-Moderate phMDA (n = 162) |
|-----------------------|------------------|----------------------------|------------------------|-------------------------------|---------------------------------|
| Females a, b          | 293 (76%)        | 52 (58%)                   | 241 (82%)              | 102 (78%)                     | 139 (86%)                       |
| Age (years) a, b      | 56.35 ± 13       | 51.96 ± 13                 | 57.69 ± 12             | 55.11 ± 12.31                 | 59.81 ± 11.59                   |
| RA Duration (years)   | 9.2 ± 8.6        | 9.57 ± 10                  | 9.1 ± 8.12             | 8.71 ± 7.71                   | 9.43 ± 8.45                     |
| RA Duration < 2 years | 70 (18%)         | 22 (24%)                   | 48 (16%)               | 20 (15%)                      | 28 (17%)                        |
| Seropositive* (n = 217) | 100 (46%)      | 15 (47%)                   | 85 (46%)               | 37 (51%)                      | 48 (43%)                        |
| TJC28* (n = 316) a, b | 10.53 ± 6.5      | 7.93 ± 6.3                 | 11.14 ± 6.4            | 9.61 ± 5.56                   | 12.39 ± 6.74                    |
| SJC28* (n = 316) a, b | 8.99 ± 6.24      | 6.17 ± 6.1                 | 9.66 ± 6.1             | 8.14 ± 5.55                   | 10.89 ± 6.26                    |
| ESR* mm/s (n = 256)   | 38.62 ± 24       | 35.37 ± 23                 | 39.4 ± 24              | 37.86 ± 23.42                 | 40.63 ± 25.02                   |
| CRP* mg/dl (n = 227) a | 2.57 ± 6        | 4.07 ± 12                  | 2.22 ± 3.15            | 2.31 ± 3.32                   | 2.15 ± 3.02                     |
| DAS28 (Imputed) b     | 5.7 ± 0.99       | 4.92 ± 1                   | 5.94 ± 0.86            | 5.62 ± 0.74                   | 6.02 ± 0.86                     |
| CDAI* (n = 296) b     | 33 ± 12.19       | 26.06 ± 12                 | 34.6 ± 12              | 30.86 ± 10.05                 | 37.62 ± 12.13                   |
| SDAI* (n = 261) b     | 35.34 ± 13       | 29.99 ± 17                 | 36.64 ± 12             | 32.66 ± 10.44                 | 39.63 ± 12.18                   |
| Physician VAS G.* (n = 298) a, b | 69.5 ± 14.8 | 62.92 ± 16                 | 71.13 ± 14             | 67.57 ± 15.12                 | 73.97 ± 12.7                    |
| Patient VAS G.* (n = 315) b | 66.11 ± 19 | 59.43 ± 25                 | 67.69 ± 17             | 63.74 ± 17.82                 | 70.93 ± 15.54                   |
| Patient VAS Pain* (n = 302) | 67.41 ± 17 | 62.93 ± 25                 | 68.5 ± 17.2            | 66.26 ± 18.57                 | 70.38 ± 15.87                   |
| HAQ (Imputed) a, b    | 0.84 ± 0.44      | 0.63 ± 0.4                 | 0.9 ± 0.5              | 0.77 ± 0.43                   | 1 ± 0.45                        |
| Euroqol* (n = 82)     | 0.34 ± 0.38      | 0.36 ± 0.4                 | 0.34 ± 0.39            | 0.4 ± 0.34                    | 0.26 ± 0.43                     |
### Persistent disease activity groups characteristics

A total 90 (23%) and 295 (77%) patients were categorized in the pRLDA and pMDA groups, respectively. Patients in the pMDA group were further categorized in subgroups plMDA and phMDA including 133 (45%) and 162 (55%) patients, respectively (Table 1). Patients in the pMDA group were older (58 ± 12 vs 52 ± 13 years; p < 0.0019 Bonferroni corrected) and more frequently females (82% vs 58%, p < 0.0019) as compared to pRLDA. At inclusion, patient disease activity (mean DAS28 4.9 ± 1.0 vs 5.9 ± 0.9, p < 0.0019) and functionality (mean HAQ 0.63 ± 0.4 vs 0.9 ± 0.5, p < 0.0019) were higher in pMDA than pRLDA respectively. Analysis within the pMDA group showed that patients in the plMDA subgroup were younger (p = 0.0005) with lower baseline disease activity (mean DAS28 5.6 ± 0.7 vs 6.0 ± 0.9, p < 0.0001) than phMDA patients. A representation of the DAS28 course for each patient in the pRLDA and pMDA groups is provided in Fig. 1 while Fig. 2 presents the 5-year disease activity course (average DAS28 in the 8 TT intervals) of groups pRLDA and pMDA and subgroups plMDA and phMDA, showing clear distinct disease activity trajectories.
pMDA group was associated with worse 5-year functionality than pRLDA

One of the main aims of this study was to investigate whether patients on pMDA have adverse long-term prognosis compared to patients on lower chronic inflammatory burden. The 5-years functionality (HAQ) trajectories (average DAS28 in the 8 TT intervals) of the pRLDA and pMDA groups are presented in Fig. 3, showing a clear distinct trajectory for each group. In multivariable mixed-effect regression analysis (Table 2), the pMDA group was associated with worse 5-year functionality trajectory than the pRLDA group (+0.28 higher HAQ trajectory in pMDA, 95% CI +0.18 to +0.39, p < 0.0001). Analysis was adjusted for possible confounding effects on gender, age and disease duration. Interestingly, the 5-year functionality was also significantly worse in females than males (+0.13 higher HAQ trajectory in females, 95% CI +0.04 to +0.23, p = 0.008) and in older patients (+0.009 higher HAQ trajectory per 1-year, 95% CI +0.006 to +0.012, p < 0.0001).

Table 2
Multivariable mixed-effect regression associated group pMDA with worse 5-year functionality (HAQ) trajectory than pRLDA group. §

| HAQ Multivariable Analysis† | Coefficient‡ | 95% CI         | p-value     |
|-----------------------------|--------------|----------------|-------------|
| Group pMDA (vs pRLDA)       | +0.28        | +0.18 to +0.39 | p < 0.0001* |
| Gender Female (vs Male)     | +0.13        | +0.04 to +0.23 | p = 0.008*  |
| Age (per year)              | +0.009       | +0.006 to +0.012 | p < 0.0001* |
| Disease Duration (per year) | +0.004       | -0.001 to +0.009 | p = 0.092   |
| Time 3–9 Months (vs baseline) | -0.203   | -0.279 to -0.126 | p < 0.0001* |
| Time 9–15 Months (vs baseline) | -0.289   | -0.366 to -0.212 | p < 0.0001* |
| Time 15–21 Months (vs baseline) | -0.288  | -0.364 to -0.213 | p < 0.0001* |
| Time 21–27 Months (vs baseline) | -0.285  | -0.362 to -0.208 | p < 0.0001* |
| Time 27–33 Months (vs baseline) | -0.347   | -0.432 to -0.261 | p < 0.0001* |
| Time 33–42 Months (vs baseline) | -0.326  | -0.399 to -0.254 | p < 0.0001* |
| Time 42–54 Months (vs baseline) | -0.323   | -0.396 to -0.251 | p < 0.0001* |
| Time 54–60 Months (vs baseline) | -0.375   | -0.448 to -0.303 | p < 0.0001* |

* Variable is associated significantly with patients’ 5-year functionality (HAQ) course (p < 0.05 significance threshold).
† Regression coefficient that represents increase (+) or decrease (-) in 5-year functionality (HAQ) course associated with the variable (category membership for categorical variable or unit increase for continuous variable).
‡ Efficiency of multivariable analysis: RMSE (Root mean square error) = 0.352, R² (R-squared) = 0.573.
§ Terms: pRLDA = Persistent Remission/Low Disease Activity Group; pMDA = Persistent Moderate Disease Activity Group.

At 5 years, although both groups had improved functionality as compared to baseline (HAQ decrease from baseline: -0.375 HAQ, 95% CI -0.448 to -0.303, p < 0.0001), pMDA group had worse functionality than pRLDA (HAQ 0.3 ± 0.31 vs 0.55 ± 0.47, p < 0.001). Notably, most of the improvement occurred within the first 12 months of treatment (HAQ decrease from baseline in first 12 months: -0.289, 95% CI -0.366 to -0.212, p < 0.0001), showing minimal additional improvement thereafter (12th up-to 60th month).

Subgroup phMDA was associated with worse 5-year functionality than plMDA

Clinical heterogeneity has been reported for the MDA group of patients on csDMARDs while limited data are available concerning bDMARDs. We assessed whether our cohort of RA patients on bDMARDs having persistent moderate disease activity represents a heterogenous group. For this, we compared lower and higher pMDA subgroups, the plMDA and phMDA, respectively. The 5-year functionality trajectories (average HAQ in the 8 TT intervals) of the patients classified in plMDA and phMDA subgroups are presented in Fig. 3, revealing a clear distinct trajectory for each subgroup. In multivariable mixed-effect
regression analysis (Table 3), the phMDA subgroup was associated with worse 5-year functionality trajectory than plMDA subgroup (+0.26 higher HAQ trajectory in pMDA, 95% CI +0.17 to +0.36, p < 0.0001). Analysis was adjusted for possible confounding effects on gender, age and disease duration. The 5-year functionality was also significantly worse in females than males (p = 0.04) and in older patients (p < 0.0001). At 5 years, group phMDA had worse functionality status than plMDA (HAQ 0.41 ± 0.38 vs 0.66 ± 0.52 respectively, p < 0.001), although both groups were associated with improved functionality as compared to baseline (HAQ decrease from baseline: -0.38 HAQ, 95% CI -0.463 to -0.297, p < 0.0001). The differentiation of 5-year functionality between subgroups plMDA and phMDA indicates heterogeneity within the pMDA group.

| HAQ Multivariable Analysis† | Coefficient‡ | 95% CI | p-value |
|-----------------------------|--------------|--------|---------|
| Group phMDA (vs plMDA)      | +0.26        | +0.17 to +0.36 | p < 0.0001* |
| Gender Female (vs Male)     | +0.12        | +0.01 to +0.24  | p = 0.04*  |
| Age (per year)              | +0.009       | +0.005 to +0.013 | p < 0.0001* |
| Disease Duration (per year) | +0.002       | -0.004 to +0.007 | p = 0.543  |
| Time 3–9 Months (vs baseline)| -0.200       | -0.287 to -0.114 | p < 0.0001* |
| Time 9–15 Months (vs baseline)| -0.285      | -0.373 to -0.196 | p < 0.0001* |
| Time 15–21 Months (vs baseline)| -0.291      | -0.378 to -0.204 | p < 0.0001* |
| Time 21–27 Months (vs baseline)| -0.279      | -0.369 to -0.190 | p < 0.0001* |
| Time 27–33 Months (vs baseline)| -0.342      | -0.444 to -0.240 | p < 0.0001* |
| Time 33–42 Months (vs baseline)| -0.308      | -0.392 to -0.225 | p < 0.0001* |
| Time 42–54 Months (vs baseline)| -0.313      | -0.396 to -0.231 | p < 0.0001* |
| Time 54–60 Months (vs baseline)| -0.380      | -0.463 to -0.297 | p < 0.0001* |

* Variable is associated significantly with patients’ 5-year functionality (HAQ) course (p < 0.05 significance threshold).
† Regression coefficient that represents increase (+) or decrease (-) in 5-year functionality (HAQ) course associated with the variable (category membership for categorical variable or unit increase for continuous variable).
‡ Efficiency of multivariable analysis: RMSE (Root mean square error) = 0.366, R² (R-squared) = 0.538.
§ Terms: plMDA = Persistent Lower-Moderate Disease Activity Group; phMDA = Persistent Higher-Moderate Disease Activity Group.

**Patient (sub)groups are associated with different serious adverse events occurrence**

We also assessed SAEs occurrence during the course of the follow-up to estimate for any differences in the long-term outcome between distinct patients groups. The 5-year cumulative SAEs trajectories of pRLDA and pMDA groups as well as of the plMDA and phMDA subgroups are presented in Fig. 4, showing a clear distinct trajectory for each group and subgroup respectively. At 5 years, pMDA group had higher occurrence of SAEs than pRLDA group (0.2 ± 0.48 in pRLDA vs 0.5 ± 0.96 in pMDA, p = 0.006). In addition, the phMDA subgroup had also higher occurrence of SAEs than the phMDA subgroup (0.32 ± 0.6 in vs 0.64 ± 1.16 respectively, p = 0.038). The differentiation between subgroups plMDA and phMDA in serious adverse events occurrence, further supports the heterogeneity within the pMDA group.

**Early predictors for classification between pRLDA and pMDA groups**

In view of the aforementioned clinically meaningful differences between pRLDA and pMDA patient groups, we developed a predictive model for the early classification of patients using data from patients’ early therapy months (first semester of treatment). Multivariable logistic regression analysis (Table 4) was used adjusting for possible confounding effects of gender, age, disease duration, previous
Classification in the pRLDA group (compared to pMLDA group) was associated with male gender (female gender OR 0.38, 95% CI 0.17 to 0.84, p = 0.017), lower baseline disease activity (DAS28 per unit: OR 0.45, 95% CI 0.29 to 0.7, p < 0.001), lower first semester's average disease activity (DAS28-average per unit: OR 0.19, 95% CI 0.12 to 0.29, p < 0.001) and functionality improvement greater than 0.22 HAQ units in first semester's compared to baseline (ΔHAQ < 0.22: OR 0.38, 95% CI 0.16 to 0.91, p = 0.029). Performance evaluation of the model in 10-fold cross-validation process yielded 88.3% accuracy, 68% sensitivity, 95% specificity and 91% area under the ROC curve.

Table 4
Multivariable logistic regression analysis to predict classification in pRLDA compared to pMDA group. §

| pRLDA Classification | Univariable Analysis | Multivariable Analysis† |
|----------------------|----------------------|-------------------------|
| (vs pMDA)            | OR 95% CI p-value    | OR 95% CI p-value       |
| Gender Female (vs Male) | 0.31 0.18 to 0.52 p < 0.001* | 0.38 0.17 to 0.84 p = 0.017* |
| Age (per year)       | 0.97 0.95 to 0.98 p < 0.001* | 0.98 0.96 to 1.02 p = 0.26 |
| Disease Duration (per year) | 1.01 0.98 to 1.03 p = 0.65 | 0.99 0.95 to 1.03 p = 0.68 |
| Previous csDMARDs, count < 2 | 1.56 0.91 to 2.67 p = 0.11 | 1.11 0.49 to 2.5 p = 0.8 |
| Anti-TNF Baseline    | 5.54 1.3 to 23.57 p = 0.02* | 2.9 0.51 to 16.55 p = 0.23 |
| DAS28 Baseline (per unit) | 0.27 0.2 to 0.38 p < 0.001* | 0.45 0.29 to 0.7 p < 0.001* |
| HAQ Baseline (per unit) | 0.21 0.11 to 0.4 p < 0.001* | 0.53 0.2 to 1.38 p = 0.19 |
| DAS28 1st Semester (per unit) | 0.17 0.11 to 0.25 p < 0.001* | 0.19 0.12 to 0.29 p < 0.001* |
| ΔHAQ 1st Semester <= 0.22 | 0.65 0.37 to 1.15 p = 0.14 | 0.38 0.16 to 0.91 p = 0.029* |

§ Terms: pRLDA = Persistent Remission/Low Disease Activity Group; pMDA = Persistent Moderate Disease Activity Group; cDMARDs = Conventional Synthetic Disease-modifying Antirheumatic Drugs; 1st Semester = Therapy Months 3–9; HAQ = Health Assessment Questionnaire; ΔHAQ = HAQ Difference 1st Semester's Average from Baseline; ACC = Accuracy; TPR = Sensitivity; TNR = Specificity; AUC = Area Under Receiver-Operating-Characteristic Curve.
† Multivariable analysis efficiency (10-fold cross-validation): ACC = 88.3%, TPR = 68%, TNR = 95%, AUC = 91%.
* Below significance threshold 0.05.

Discussion

We characterized the long-term prognosis of RA patients with persistent moderate disease activity (MDA) under bDMARDs treatment in the context of clinical practice. We found that a substantial proportion of patients although improved disease activity status and function, still manifest pMDA irrespective of treatment modifications. Most importantly, pMDA was associated with worse long-term (5-year) outcomes (functional limitation and serious adverse events) than persistent lower inflammatory burden. Interestingly, the subgroup with persistently lower-MDA had better long-term outcomes than those with persistently higher-MDA.

An important finding of this study was that persistent MDA was linked to significantly worse functionality trajectory and higher occurrence of serious adverse events during 5 years of bDMARDs therapy, as compared to persistent low disease activity or remission (Fig. 3 and Table 2). Interestingly, residual disease activity was the major contributor to HAQ increase over time (Table 2). These data are comparable to those from early RA cohorts on csDMARDs assessing the cumulative effect of disease activity on RA-related outcomes (9, 10, 12). Although one might argue that this finding is an expected one, we considered clinically important and novel to focus for the first time on patients treated with bDMARDs, which might exert differential immunomodulatory effects as compared to csDMARDs. For example, it has
been shown that both TNFi and tocilizumab may inhibit joint destruction effectively even when residual disease activity exists, which is not the case for methotrexate (13–15).

Another key finding of our study is that MDA patients comprise a heterogeneous group in terms of outcome. Patients with persistent lower-MDA (plMDA) have significantly better 5-year functionality trajectory than those in persistent higher-MDA (phMDA). This agrees with studies focusing on early-onset RA and csDMARDs treatments, showing that patients on the lower end of MDA have significantly better outcomes than those on the higher end (10, 16). Notwithstanding the fact that observational studies cannot provide direct support for management strategies, we consider our results to be of clinical importance and relevant to the T2T concept. Firstly, our data provide further support to the validity of T2T in clinical practice, since there was a clear superiority for all long-term outcomes in the persistent remission/low as compared to persistent moderate disease activity group. Moreover, the heterogeneity of outcomes in lower and higher MDA patients can assist T2T strategies to tailor treatments for these subgroups in order to improve outcomes.

Long-term prognosis of RA largely depends on the disease inflammatory burden and associated comorbidities. One of the limitations in the literature, is that the majority of short- and even long-term studies evaluate RA-related inflammation cross-sectionally (single time-point). However, values representative of longitudinal course of disease activity and its effect over time are considered to provide more valuable information. One such approach is the average disease activity from multiple years of treatment (10), while another is the area under the curve of DAS28 course which was associated with both radiographic progression (17) and the risk for cardiovascular diseases (CVD) (18, 19). In the present study, we applied the cumulative time percentage (CTP) that DAS28 falls within a specified range during follow-up (CTP of DAS28-range), as indicative of long-term longitudinal disease activity course. We consider our approach more appropriate for patient group classification than using AUC of DAS28-course for the following reasons. Firstly, compared to the AUC, the CTP is interpretable and flexible enough to support more restricted or loose specifications of MDA (different CTP thresholds). Secondly, it imposes a constraint for a proportion of the treatment course (≥ 50%) to exhibit moderate disease activity while it intelligently ignores possible fluctuations in the rest of the proportion. Finally, and most importantly, the AUC method may not be able to distinguish a persistent moderate disease activity trajectory from one fluctuating equally between low and high disease activity levels, since these trajectories may exhibit approximately equivalent AUC values.

Studies analyzing persistent disease activity status from cohorts of biologics have focused on persistent remission (20–26). Herein we focused on persistent residual disease activity (pMDA), and we found that from patients in persistent moderate or lower inflammatory burden treated on bDMARDs, 23% were classified in a persistent low or remission status while 77% still exhibited substantial inflammatory burden (pMDA) after 5 years of therapy. Even though this seems as a rather high number, yet available data from registries have shown that only 8.2–21% of bDMARDs treated patients are classified as being in persistent remission (20–23, 25). Of note, pMDA patients in our cohort differ from pRLDA even from baseline and could be divided further in two heterogenous subgroups. Multivariable analysis revealed
gender, lower disease activity (DAS28) at baseline and at first semester’s average and functionality improvement (greater than 0.22 HAQ units) in first semester’s average compared to baseline, as significant predictors for early classification in persistent low compared to moderate disease activity status (Table 4).

One of the limitations of this study is patients’ missing follow-up data. In order to address missing data and also maintain data quality, we excluded patients with large percentage of missing DAS28-data (> 50%) and imputed missing DAS28-data in the rest of the patients. Of note, the imputed-dataset (385 patients) compared to the non-imputed (292 patients) included additionally 93 (24%) patients, and results were similar in both datasets (groups pRLDA and pMDA differentiated in functionality trajectory and SAEs, data not shown).

Another limitation of this study can be considered the merging of remission and low disease activity groups. The pRLDA group included 52 patients in persistent remission, 20 in persistent low disease activity and 18 with fluctuations between low and remission disease activity. Future studies in larger datasets could focus in persistent strictly-low (2.6 ≤ DAS28 ≤ 3.2) and persistent moderate (3.2 < DAS28 ≤ 5.1) disease activity comparison.

In order to evaluate the robustness of the methodological approach, we performed sensitivity analysis in shorter (3-year) therapy duration with similar results (groups pRLDA and pMDA differentiated in functionality trajectory). Furthermore, analysis on groups’ differences regarding patients’ inclusion-year (year ≤ 2007, 2007 < year ≤ 2010, year > 2010) did not yield significant variation between the groups.

Conclusions

Our analysis revealed that a considerable proportion of RA patients on bDMARDs in clinical practice, although improve disease activity status, still manifest persistent moderate disease activity. This state was associated with adverse 5-year outcomes and was also found to present internal heterogeneity, while predictors were analyzed to assist for early patient classification. These findings further support the value of T2T strategy in order to improve long-term outcome and highlight the need for further targeted studies on persistent MDA state and its heterogenous subgroups.

Abbreviations

RA: Rheumatoid Arthritis; MDA: Moderate Disease Activity; pMDA: Persistent Moderate Disease Activity; pRLDA: Persistent Remission or Low Disease Activity; pLMDA: Persistent Lower Moderate Disease Activity; phMDA: Persistent Higher Moderate Disease Activity; HAQ: Health Assessment Questionnaire for Functionality Assessment; SAEs: Serious Adverse Events; bDMARDs: Biologic Disease-modifying Antirheumatic Drugs; csDMARDs: Conventional Synthetic Disease-modifying Antirheumatic Drugs; HeRBT: Hellenic Registry of Biologic Therapies; DAS28: Disease Activity Score of 28 Joint Counts; TNFis: TNFα inhibitors; TT: Clinically Relevant Therapy Time Intervals; CTP: Cumulative Time Percentage; ΔHAQ:
HAQ Difference; ACC: Accuracy; TPR: Sensitivity or True Positive Rate; TNR: Specificity or True Negative Rate; AUC: Area Under the Receiver-operating-characteristic Curve; CV: Cross-validation; T2T: Treat to Target.

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from the Institutional Review-Board of the University Hospital of Heraklion, Crete (decision-number:1476/20-03-2012). Participants provided informed consents.

Consent for publication

Not applicable.

Availability of data and materials

The data and analytic methods that support the findings of this study are available to qualified investigators by request to the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported in 2018 by the Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Technology (GSRT), under the HFRI PhD Fellowship grant (no 1722), under the HFRI PhD Fellowship grant [grant number 1722].

Author’s contributions

IG, IF and PS authors were involved in the design and statistical analysis of the study as well as manuscript drafting and approval of the final version while the rest of the authors contributed equally in consulting, manuscript proofreading and approval.

Acknowledgements

The authors acknowledge the collaboration of all consultant rheumatologists and their specialist nurses for the acquisition, maintenance and provision of the data. Specifically, the authors thank the following collaborators: Argyro Repa (MD), Nestor Avgoustidis (MD), Nikolaos Kougkas (MD), Ioannis Papalopoulos (MD), Styliani Polia (RN), Eleni Kampouraki (RN) from the Rheumatology and Clinical Immunology Clinic, University General Hospital of Heraklion (PAGNI), Heraklion, Crete, Greece.
References

1. Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008;58(9):2622–31.

2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.

3. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.

4. Hetland M, Christensen I, Tarp U, Dreyer L, Hansen A, Hansen I, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–54.

5. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134–42.

6. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447–57.

7. Gabay C, Riek M, Scherer A, Finckh A. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology. 2015;54(9):1664–72.

8. Forsblad-d’Elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology. 2015;54(7):1186–93.

9. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daures JP, et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis. 2015;74(4):724–9.

10. Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh DA, et al. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis. 2016;75(12):2080–6.

11. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, et al. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with
Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol. 2018;45(6):785–94.

12. Cook MJ, Diffin J, Scire CA, Lunt M, MacGregor AJ, Symmons DP, et al. Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology. 2016;55(9):1601–9.

13. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006;54(10):3119–25.

14. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52(4):1020–30.

15. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687–93.

16. Kiely P, Walsh D, Williams R, Young A, Early Rheumatoid Arthritis N. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology. 2011;50(5):926–31.

17. Tsuji H, Yano K, Furu M, Yamakawa N, Ikari K, Hashimoto M, et al. Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. Sci Rep. 2017;7(1):5856.

18. Arts EE, Fransen J, Den Broeder AA, van Riel P, Popa CD. Low disease activity (DAS28</=3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):1693–9.

19. Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(6):998–1003.

20. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine. 2009;76(4):350–5.

21. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011;63(6):856–64.

22. Einarsson JT, Geborek P, Saxne T, Kapetanovic MC. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. J Rheumatol. 2015;42(5):741–8.
23. Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, et al. Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther. 2013;15(6):R221.

24. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389–95.

25. Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol. 2014;41(8):1607–13.

26. Hamann P, Holland R, Hyrich K, Pauling JD, Shaddick G, Nightingale A, et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783–93.

Figures

Figure 1

DAS28 5-year disease activity course for each cohort patient (imputed data). RA: Rheumatoid Arthritis; DAS28: Disease activity score with 28 joint counts; pRLDA: Patients with persistent remission or low disease activity; pMDA: Patients with persistent moderate disease activity; pMDA: Patients with
persistent lower moderate disease activity; phMDA: Patients with persistent higher moderate disease activity.

**Figure 2**

DAS28 trajectories of patient groups pRLDA (remission-low), pMDA (moderate) and subgroups plMDA (lower-moderate), phMDA (higher-moderate). RA: Rheumatoid Arthritis; DAS28: Disease activity score with 28 joint counts; pRLDA: Patients with persistent remission or low disease activity; pMDA: Patients with
persistent moderate disease activity; pMDA: Patients with persistent lower moderate disease activity; phMDA: Patients with persistent higher moderate disease activity.

**Figure 3**

HAQ trajectories of patient groups pRLDA (remission-low), pMDA (moderate) and subgroups pIMDA (lower-moderate), phMDA (higher-moderate). RA: Rheumatoid Arthritis; HAQ: Functionality measured by Health Assessment Questionnaire; pRLDA: Patients with persistent remission or low disease activity;
pMDA: Patients with persistent moderate disease activity; plMDA: Patients with persistent lower moderate disease activity; phMDA: Patients with persistent higher moderate disease activity.

Figure 4

Serious adverse events trajectories of groups pRLDA (remission-low), pMDA (moderate) and subgroups plMDA and phMDA. RA: Rheumatoid Arthritis; pRLDA: Patients with persistent remission or low disease activity; pMDA: Patients with persistent moderate disease activity; plMDA: Patients with persistent lower moderate disease activity; phMDA: Patients with persistent higher moderate disease activity.
